news
Novel Immunotherapy Combination Shows Promise in HPV16-Positive R/M Head and Neck Cancer: Insights from the VERSATILE-002 Phase 2 Trial
PDS0101 combined with pembrolizumab demonstrated encouraging efficacy and safety in immune checkpoint inhibitor-naive HPV16-positive recurrent/metastatic head and neck squamous cell carcinoma, supporting further first-line evaluation.
